Literature DB >> 15566731

Antiviral susceptibility testing of cytomegalovirus: criteria for detecting resistance to antivirals.

W L Drew1, R Miner, E Saleh.   

Abstract

Testing cytomegaloviruses for antiviral susceptibility is increasing especially since the reports of 'resistance' to ganciclovir and foscarnet (Erice et al., 1989; Knox et al., 1991). There is however no standardized method for susceptibility testing nor are there criteria for designating an isolate as sensitive or resistant. In a previous paper we utilized a plaque reduction assay and suggested that a resistant strain be defined as one requiring > 12 microM ganciclovir for inhibition of 50% of viral plaques. (Drew et al., 1991) This concentration was chosen because it was at least four-fold greater than the mean concentration required to inhibit pretherapy isolates. In this paper we present the results of testing a large number of isolates prior to and during therapy with either ganciclovir or foscarnet. By analyzing the results of these assays we propose revised criteria for susceptibility of cytomegalovirus </= 5 microM for ganciclovir and <400 microM for foscarnet.

Entities:  

Year:  1993        PMID: 15566731     DOI: 10.1016/0928-0197(93)90012-t

Source DB:  PubMed          Journal:  Clin Diagn Virol        ISSN: 0928-0197


  18 in total

1.  Limitations of cytomegalovirus testing.

Authors:  J Harmenberg; M Brytting
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

2.  A nine-codon deletion mutation in the cytomegalovirus UL97 phosphotransferase gene confers resistance to ganciclovir.

Authors:  S Chou; C L Meichsner
Journal:  Antimicrob Agents Chemother       Date:  2000-01       Impact factor: 5.191

3.  Intravitreal, retinal, and central nervous system foscarnet concentrations after rapid intravenous administration to rabbits.

Authors:  L F López-Cortés; R Ruiz-Valderas; M J Lucero-Muñoz; E Cordero; M T Pastor-Ramos; J Marquez
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

4.  Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories.

Authors:  S Chou; N S Lurain; A Weinberg; G Y Cai; P L Sharma; C S Crumpacker
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

5.  Use of time-saving flow cytometry for rapid determination of resistance of human cytomegalovirus to ganciclovir.

Authors:  Gyu-Cheol Lee; Dong-Gun Lee; Su-Mi Choi; Jin-Hong Yoo; Sun-Hee Park; Jung-Hyun Choi; Woo-Sung Min; Ok-Hee Cho; Chan-Hee Lee; Wan-Shik Shin
Journal:  J Clin Microbiol       Date:  2005-10       Impact factor: 5.948

6.  Drug-resistant herpesviruses: should we look for them?

Authors:  G Boivin
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-08       Impact factor: 3.267

7.  Differentiated Levels of Ganciclovir Resistance Conferred by Mutations at Codons 591 to 603 of the Cytomegalovirus UL97 Kinase Gene.

Authors:  Sunwen Chou; Ronald J Ercolani; Adam L Vanarsdall
Journal:  J Clin Microbiol       Date:  2017-04-26       Impact factor: 5.948

Review 8.  Resistance of human cytomegalovirus to antiviral drugs.

Authors:  A Erice
Journal:  Clin Microbiol Rev       Date:  1999-04       Impact factor: 26.132

Review 9.  The genetic basis of human cytomegalovirus resistance and current trends in antiviral resistance analysis.

Authors:  S H James; M N Prichard
Journal:  Infect Disord Drug Targets       Date:  2011-10

10.  Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients.

Authors:  K C Cundy; B G Petty; J Flaherty; P E Fisher; M A Polis; M Wachsman; P S Lietman; J P Lalezari; M J Hitchcock; H S Jaffe
Journal:  Antimicrob Agents Chemother       Date:  1995-06       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.